-DOCSTART- -X- O
INTRODUCTION -X- _ O
: -X- _ O
Dengue -X- _ B-Patient
infection -X- _ I-Patient
is -X- _ O
the -X- _ O
fastest -X- _ O
spreading -X- _ O
mosquito-borne -X- _ O
viral -X- _ O
disease -X- _ O
in -X- _ O
the -X- _ O
world. -X- _ O
One -X- _ O
of -X- _ O
the -X- _ O
complications -X- _ O
of -X- _ O
dengue -X- _ O
is -X- _ O
dehydration -X- _ O
which -X- _ O
, -X- _ O
if -X- _ O
not -X- _ O
carefully -X- _ O
monitored -X- _ O
and -X- _ O
treated -X- _ O
, -X- _ O
may -X- _ O
lead -X- _ O
to -X- _ O
shock -X- _ O
, -X- _ O
particularly -X- _ O
in -X- _ O
those -X- _ O
with -X- _ O
dengue -X- _ O
haemorrhagic -X- _ O
fever. -X- _ O
WHO -X- _ O
has -X- _ O
recommended -X- _ O
oral -X- _ O
fluid -X- _ O
intake -X- _ O
of -X- _ O
five -X- _ O
glasses -X- _ O
or -X- _ O
more -X- _ O
for -X- _ O
adults -X- _ O
who -X- _ O
are -X- _ O
suspected -X- _ O
to -X- _ O
have -X- _ O
dengue -X- _ O
fever. -X- _ O
However -X- _ O
, -X- _ O
there -X- _ O
have -X- _ O
been -X- _ O
no -X- _ O
published -X- _ O
studies -X- _ O
looking -X- _ O
at -X- _ O
self-care -X- _ B-Intervention
intervention -X- _ I-Intervention
measures -X- _ I-Intervention
to -X- _ I-Intervention
improve -X- _ I-Intervention
oral -X- _ I-Intervention
fluid -X- _ I-Intervention
intake -X- _ I-Intervention
among -X- _ O
patients -X- _ B-Patient
suspected -X- _ I-Patient
of -X- _ I-Patient
dengue -X- _ I-Patient
fever. -X- _ I-Patient
OBJECTIVE -X- _ O
: -X- _ O
To -X- _ O
assess -X- _ O
the -X- _ O
feasibility -X- _ O
and -X- _ O
effectiveness -X- _ O
of -X- _ O
using -X- _ O
a -X- _ O
fluid -X- _ B-Intervention
chart -X- _ I-Intervention
to -X- _ I-Intervention
improve -X- _ I-Intervention
oral -X- _ I-Intervention
fluid -X- _ I-Intervention
intake -X- _ I-Intervention
in -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
suspected -X- _ I-Patient
dengue -X- _ I-Patient
fever -X- _ I-Patient
in -X- _ O
a -X- _ O
primary -X- _ O
care -X- _ O
setting. -X- _ O
METHODS -X- _ O
: -X- _ O
This -X- _ O
feasibility -X- _ O
study -X- _ O
used -X- _ O
a -X- _ O
randomized -X- _ O
controlled -X- _ O
study -X- _ O
design. -X- _ O
The -X- _ O
data -X- _ O
was -X- _ O
collected -X- _ O
over -X- _ O
two -X- _ O
months -X- _ O
at -X- _ O
a -X- _ O
primary -X- _ O
care -X- _ O
clinic -X- _ O
in -X- _ O
a -X- _ O
teaching -X- _ O
hospital. -X- _ O
The -X- _ O
inclusion -X- _ O
criteria -X- _ O
were -X- _ O
: -X- _ O
age -X- _ B-Patient
> -X- _ I-Patient
12 -X- _ I-Patient
years -X- _ I-Patient
, -X- _ I-Patient
patients -X- _ I-Patient
who -X- _ I-Patient
were -X- _ I-Patient
suspected -X- _ I-Patient
to -X- _ I-Patient
have -X- _ I-Patient
dengue -X- _ I-Patient
fever -X- _ I-Patient
based -X- _ O
on -X- _ O
the -X- _ O
assessment -X- _ O
by -X- _ O
the -X- _ O
primary -X- _ O
healthcare -X- _ O
clinician -X- _ O
, -X- _ O
fever -X- _ O
for -X- _ O
> -X- _ O
three -X- _ O
days -X- _ O
, -X- _ O
and -X- _ O
thrombocytopenia -X- _ O
( -X- _ O
platelets -X- _ O
< -X- _ O
150 -X- _ O
x -X- _ O
10 -X- _ O
( -X- _ O
9 -X- _ O
) -X- _ O
/ -X- _ O
L -X- _ O
) -X- _ O
. -X- _ O
Both -X- _ O
groups -X- _ O
received -X- _ O
a -X- _ O
dengue -X- _ O
home -X- _ O
care -X- _ O
card. -X- _ O
The -X- _ O
intervention -X- _ B-Intervention
group -X- _ I-Intervention
received -X- _ I-Intervention
the -X- _ I-Intervention
fluid -X- _ I-Intervention
chart -X- _ I-Intervention
and -X- _ I-Intervention
a -X- _ I-Intervention
cup -X- _ I-Intervention
( -X- _ I-Intervention
200ml -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
Baseline -X- _ O
clinical -X- _ O
and -X- _ O
laboratory -X- _ O
data -X- _ O
, -X- _ O
24-hour -X- _ O
fluid -X- _ O
recall -X- _ O
( -X- _ O
control -X- _ O
group -X- _ O
) -X- _ O
, -X- _ O
and -X- _ O
fluid -X- _ O
chart -X- _ O
were -X- _ O
collected. -X- _ O
The -X- _ O
main -X- _ O
outcomes -X- _ O
were -X- _ O
: -X- _ O
hospitalization -X- _ O
rates -X- _ O
, -X- _ O
intravenous -X- _ O
fluid -X- _ O
requirement -X- _ O
and -X- _ O
total -X- _ O
oral -X- _ O
fluid -X- _ O
intake. -X- _ O
FINDINGS -X- _ O
: -X- _ O
Among -X- _ B-Outcome
the -X- _ I-Outcome
138 -X- _ I-Outcome
participants -X- _ I-Outcome
who -X- _ I-Outcome
were -X- _ I-Outcome
included -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
final -X- _ I-Outcome
analysis -X- _ I-Outcome
, -X- _ I-Outcome
there -X- _ I-Outcome
were -X- _ I-Outcome
fewer -X- _ I-Outcome
hospital -X- _ I-Outcome
admissions -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
intervention -X- _ I-Outcome
group -X- _ I-Outcome
( -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
7 -X- _ I-Outcome
, -X- _ I-Outcome
10.0 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
than -X- _ I-Outcome
the -X- _ I-Outcome
control -X- _ I-Outcome
group -X- _ I-Outcome
( -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
12 -X- _ I-Outcome
, -X- _ I-Outcome
17.6 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.192 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Similarly -X- _ I-Outcome
, -X- _ I-Outcome
fewer -X- _ I-Outcome
patients -X- _ I-Outcome
( -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
9 -X- _ I-Outcome
, -X- _ I-Outcome
12.9 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
intervention -X- _ I-Outcome
group -X- _ I-Outcome
required -X- _ I-Outcome
intravenous -X- _ I-Outcome
fluid -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
control -X- _ I-Outcome
group -X- _ I-Outcome
( -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
15 -X- _ I-Outcome
, -X- _ I-Outcome
22.1 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.154 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
There -X- _ I-Outcome
was -X- _ I-Outcome
an -X- _ I-Outcome
increase -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
amount -X- _ I-Outcome
of -X- _ I-Outcome
daily -X- _ I-Outcome
oral -X- _ I-Outcome
fluid -X- _ I-Outcome
intake -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
intervention -X- _ I-Outcome
group -X- _ I-Outcome
( -X- _ I-Outcome
about -X- _ I-Outcome
3,000 -X- _ I-Outcome
ml -X- _ I-Outcome
) -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
control -X- _ I-Outcome
group -X- _ I-Outcome
( -X- _ I-Outcome
about -X- _ I-Outcome
2,500 -X- _ I-Outcome
ml -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.521 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
However -X- _ I-Outcome
, -X- _ I-Outcome
these -X- _ I-Outcome
differences -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
reach -X- _ I-Outcome
statistical -X- _ I-Outcome
significance. -X- _ I-Outcome
CONCLUSION -X- _ O
: -X- _ O
This -X- _ O
is -X- _ O
a -X- _ O
feasible -X- _ O
and -X- _ O
acceptable -X- _ O
study -X- _ O
to -X- _ O
perform -X- _ O
in -X- _ O
a -X- _ O
primary -X- _ O
care -X- _ O
setting. -X- _ O
The -X- _ O
fluid -X- _ O
chart -X- _ O
is -X- _ O
a -X- _ O
simple -X- _ O
, -X- _ O
inexpensive -X- _ O
tool -X- _ O
that -X- _ O
may -X- _ O
reduce -X- _ O
hospitalization -X- _ O
and -X- _ O
intravenous -X- _ O
fluid -X- _ O
requirement -X- _ O
in -X- _ O
suspected -X- _ O
dengue -X- _ O
patients. -X- _ O
A -X- _ O
randomized -X- _ O
controlled -X- _ O
trial -X- _ O
with -X- _ O
larger -X- _ O
sample -X- _ O
size -X- _ O
is -X- _ O
needed -X- _ O
to -X- _ O
determine -X- _ O
this -X- _ O
conclusively. -X- _ O
TRIAL -X- _ O
REGISTRATION -X- _ O
: -X- _ O
International -X- _ O
Standard -X- _ O
Randomized -X- _ O
Controlled -X- _ O
Trial -X- _ O
Number -X- _ O
( -X- _ O
ISRCTN -X- _ O
) -X- _ O
Registry -X- _ O
ISRCTN25394628 -X- _ O
http -X- _ O
: -X- _ O
/ -X- _ O
/ -X- _ O
www.isrctn.com -X- _ O
/ -X- _ O
ISRCTN25394628 -X- _ O

